Theranostic Profiling for Actionable Aberrations in Advanced High Risk Osteosarcoma with Aggressive Biology Reveals High Molecular Diversity: The Human Fingerprint Hypothesis (Q34025926)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Theranostic Profiling for Actionable Aberrations in Advanced High Risk Osteosarcoma with Aggressive Biology Reveals High Molecular Diversity: The Human Fingerprint Hypothesis	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Theranostic Profiling for Actionable Aberrations in Advanced High Risk Osteosarcoma with Aggressive Biology Reveals High Molecular Diversity: The Human Fingerprint Hypothesis (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

molecular diversity

1 reference

based on heuristic

inferred from title

author name string

Daniela Egas-Bejar

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Pete M Anderson

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Rishi Agarwal

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Fernando Corrales-Medina

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Eswaran Devarajan

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Winston W Huh

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Robert E Brown

7

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Vivek Subbiah

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

publication date

1 March 2014

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

167-179

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Update on targets and novel treatment options for high-grade osteosarcoma and chondrosarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

5 July 2018

A systematic review of p53 as a biomarker of survival in patients with osteosarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

5 July 2018

Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

5 July 2018

Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

5 July 2018

Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

5 July 2018

SC-1, a sorafenib derivative, shows anti-tumor effects in osteogenic sarcoma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

5 July 2018

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

5 July 2018

High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

5 July 2018

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

5 July 2018

Cyclin E1 is amplified and overexpressed in osteosarcoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

5 July 2018

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

5 July 2018

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

5 July 2018

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

5 July 2018

A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

5 July 2018

The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

5 July 2018

Impaired bone development and increased mesenchymal progenitor cells in calvaria of RB1-/- mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

5 July 2018

Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

5 July 2018

Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

5 July 2018

BCL2L2 is a probable target for novel 14q11.2 amplification detected in a non-small cell lung cancer cell line

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

5 July 2018

Novel therapeutic approaches in pediatric and young adult sarcomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

5 July 2018

Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

5 July 2018

MET overexpression turns human primary osteoblasts into osteosarcomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

5 July 2018

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

5 July 2018

Transient excess of MYC activity can elicit genomic instability and tumorigenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

5 July 2018

Tyrosine phosphatase PTPRD suppresses colon cancer cell migration in coordination with CD44.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

29 October 2018

High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

29 October 2018

Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

29 October 2018

Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

29 October 2018

Expression and Prognostic Significance of CD151, c-Met, and Integrin alpha3/alpha6 in Pancreatic Ductal Adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

29 October 2018

The role of TTF-1 in differentiating primary and metastatic lung adenocarcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128257

29 October 2018

[TTF-1: neither angel nor demon]

1 reference

https://pubmed.ncbi.nlm.nih.gov/25126591

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways

1 reference

https://pubmed.ncbi.nlm.nih.gov/25126591

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The germline TP53 mutation c.722 C>T promotes bone and liver tumorigenesis at a young age

1 reference

https://pubmed.ncbi.nlm.nih.gov/25126591

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma)

1 reference

https://pubmed.ncbi.nlm.nih.gov/25126591

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Morphogenomics and morphoproteomics: a role for anatomic pathology in personalized medicine

1 reference

https://pubmed.ncbi.nlm.nih.gov/25126591

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expressions of p53, c-MYC, BCL-2 and apoptotic index in human osteosarcoma and their correlations with prognosis of patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/25126591

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.18632/ONCOSCIENCE.21

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34025926&oldid=2229982982"